Equities Analysts Set Expectations for KROS Q1 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities research analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Keros Therapeutics in a note issued to investors on Thursday, February 27th. William Blair analyst M. Phipps expects that the company will post earnings of ($0.61) per share for the quarter. William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Keros Therapeutics' current full-year earnings is ($4.74) per share. William Blair also issued estimates for Keros Therapeutics' Q2 2026 earnings at ($0.62) EPS, Q3 2026 earnings at ($0.62) EPS, Q4 2026 earnings at ($0.62) EPS and FY2028 earnings at ($2.14) EPS.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.36) by $0.22. The firm had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%.

KROS has been the topic of several other reports. Wedbush lowered Keros Therapeutics from an "outperform" rating to a "neutral" rating and reduced their target price for the company from $47.00 to $15.00 in a research report on Friday, January 17th. TD Cowen downgraded shares of Keros Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Wells Fargo & Company lowered their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, February 27th. Truist Financial cut their price target on shares of Keros Therapeutics from $100.00 to $43.00 and set a "buy" rating on the stock in a research note on Monday, December 23rd. Finally, HC Wainwright lowered their price objective on shares of Keros Therapeutics from $47.00 to $40.00 and set a "buy" rating for the company in a research note on Thursday, February 27th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Keros Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $42.33.

Remove Ads

Keros Therapeutics Trading Up 0.7 %

Shares of KROS stock traded up $0.09 during trading hours on Monday, reaching $11.76. 168,882 shares of the company's stock were exchanged, compared to its average volume of 1,549,036. Keros Therapeutics has a fifty-two week low of $9.77 and a fifty-two week high of $72.37. The stock's 50 day moving average is $12.20 and its 200-day moving average is $38.82. The company has a market cap of $476.81 million, a price-to-earnings ratio of -2.25 and a beta of 1.39.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Braidwell LP grew its stake in shares of Keros Therapeutics by 167.9% during the 4th quarter. Braidwell LP now owns 1,894,439 shares of the company's stock worth $29,989,000 after purchasing an additional 1,187,199 shares during the period. Point72 Asset Management L.P. grew its position in Keros Therapeutics by 155.9% during the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock valued at $55,025,000 after buying an additional 577,220 shares during the period. Lynx1 Capital Management LP purchased a new position in Keros Therapeutics in the fourth quarter valued at $8,612,000. Millennium Management LLC increased its holdings in Keros Therapeutics by 53.3% in the fourth quarter. Millennium Management LLC now owns 878,159 shares of the company's stock valued at $13,901,000 after buying an additional 305,169 shares in the last quarter. Finally, Alkeon Capital Management LLC raised its position in shares of Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company's stock worth $110,194,000 after acquiring an additional 298,694 shares during the period. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.